The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma
Open accessAbstract
BACKGROUND/AIM: Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies, remaining generally incurable. Histone deacetylase (HDAC) seems to play a role in regulating transcription of genes involved in ATC, making HDAC inhibitors (HDACI) promising anticancer drugs for ATC. The purpose of this review was to evaluate the role of HDACIs in ATC treatment and describe the latest trends of current research on this field. MATERIALS AND METHODS: This literature review was performed using the MEDLINE database. The keywords/phrases were; thyroid cancer, anaplastic, HDAC, histone, deacetylase*, HDACI. RESULTS: Compounds, such as SuberoylAnilide Hydroxamic Acid, valproic acid, sodium butyrate, butyrate, phenylbutyrate, trichostatin A, AB1-13, panobinostat or LBH589, belinostat, MS-275, depsipeptide, CUDC101, CUDC907, N-Hydroxy-7-(2-naphthylthio)-Hepanomide (HNHA), and PXD101 have shown promising antitumor effects against ATC. CONCLUSION: HDACIs represent a promising therapy for ATC management, both as monotherapy and in combination with other anticancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chan, D. B. Y., Zheng, Y., Tyner, J. W., Chng, W. J., Chien, W. W., Gery, S., Leong, G., Braunstein, G. D., & Koeffler, H. P. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1465-6 · Cited by 47
RetractedNuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase
Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80218-4 · Cited by 1,230
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 938
Histone deacetylase inhibitors: Potential in cancer therapy
Marks, P. A., & Xu, W. ‐. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22185 · Cited by 724
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Gallinari, P., Marco, S. D., Jones, P., Pallaoro, M., & Steinkühler, C. (2007) · Cell Research · doi:10.1038/sj.cr.7310149 · Cited by 678
Anaplastic thyroid carcinoma: A 50-year experience at a single institution
McIver, B., HAY, I. D., Giuffrida, D., et al. (2001) · Surgery · doi:10.1067/msy.2001.118266 · Cited by 484
Anaplastic Thyroid Carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment Approaches
Are, C., & Shaha, A. R. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.05.042 · Cited by 440
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Duvic, M., & Vu, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1111 · Cited by 345
Tennvall, J., Lundell, G. E. F., Wahlberg, P., Bergenfelz, A. O. J., Grimelius, L., Åkerman, M., Skog, A.-L. H., & Wallin, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600361 · Cited by 235
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer
Damaskos, C., Valsami, S. I., Kontos, M. C., Spartalis, E. D., Kalampokas, T., Kalampokas, E., Athanasiou, A., Moris, D., Daskalopoulou, A., Davakis, S., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11286 · Cited by 190
Self-citationPetruzzella, E., Sirota, R., Solazzo, I., Gandin, V., & Gibson, D. (2018) · Chemical Science · doi:10.1039/c8sc00428e · Cited by 155
Furuya, F., Shimura, H., Suzuki, H., Taki, K., Ohta, K., Haraguchi, K., Onaya, T., Endo, T., & Kobayashi, T. (2004) · Endocrinology · doi:10.1210/en.2003-1258 · Cited by 153
Woyach, J. A., Kloos, R. T., Ringel, M. D., Arbogast, D., Collamore, M., Zwiebel, J. A., Grever, M. R., Villalona-Calero, M. A., & Shah, M. H. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1631 · Cited by 151
Hou, P., Bojdani, E., & Xing, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1888 · Cited by 128
Catalano, M. G., Fortunati, N., Pugliese, M., Poli, R., Bosco, O., Mastrocola, R., Aragno, M., & Boccuzzi, G. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06970 · Cited by 121
Luong, Q. T., O’Kelly, J., Braunstein, G. D., Hershman, J. M., & Koeffler, H. P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0367 · Cited by 98
Garmpis, N., Damaskos, C., Garmpi, A., Kalampokas, E., Kalampokas, T., Spartalis, E. D., Daskalopoulou, A., Valsami, S. I., Kontos, M. C., Nonni, A., et al. (2017) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20041 · Cited by 96
Self-citationFortunati, N., Catalano, M. G., Arena, K., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031407 · Cited by 92
Puppin, C., D’Aurizio, F., D'Elia, A. V., Cesaratto, L., Tell, G., Russo, D., Filetti, S., Ferretti, E., Tosi, E., Mattei, T., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0128 · Cited by 88
Kotian, S., Zhang, L., Boufraqech, M., Gaskins, K., Gara, S. K., Quezado, M., Nilubol, N., & Kebebew, E. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1043 · Cited by 88
Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer
Mitsiades, C. S., Poulaki, V., McMullan, C. J., Negri, J. M., Fanourakis, G., Goudopoulou, A., Richon, V. M., Marks, P. A., & Mitsiades, N. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0776 · Cited by 87
MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells
Brest, P., Lassalle, S., Hofman, V., Bordone, O., Tanga, V., Bonnetaud, C., Moreilhon, C., Rios, G., Santini, J., Barbry, P., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0257 · Cited by 85
Epigenetics of thyroid cancer and novel therapeutic targets
Russo, D., Damante, G., Puxeddu, E., Durante, C., & Filetti, S. (2011) · Journal of Molecular Endocrinology · doi:10.1530/jme-10-0150 · Cited by 83
Greenberg, V. L., Williams, J. M., Cogswell, J. P., Mendenhall, M. D., & Zimmer, S. G. (2001) · Thyroid · doi:10.1089/10507250152039046 · Cited by 71
Borbone, E., Berlingieri, M. T., Bellis, F. D., Nebbioso, A., Chiappetta, G., Mai, A., Altucci, L., & Fusco, A. (2009) · Oncogene · doi:10.1038/onc.2009.306 · Cited by 70
Sherman, E. J., Su, Y. B., Lyall, A., Schöder, H. M., Fury, M. G., Ghossein, R. A., Haque, S. S., Lisa, D., Shaha, A. R., Tuttle, R. M., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0393 · Cited by 69
Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.
Tsilimigras, D., Ntanasis-Stathopoulos, I., Moris, D., Spartalis, E., & Pawlik, T. (2018) · Surgical oncology · doi:10.1016/j.suronc.2018.07.015 · Cited by 69
Self-citationCatalano, M. G., Pugliese, M., Gargantini, E., Grange, C., Bussolati, B., Asioli, S., Bosco, O., Poli, R., Compagnone, A., Bandino, A., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26057 · Cited by 56
Akagi, T., Luong, Q. T., Gui, D., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604544 · Cited by 49
Catalano, M. G., Fortunati, N., Pugliese, M., Marano, F., Ortoleva, L., Poli, R., Asioli, S., Bandino, A., Palestini, N., Grange, C., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2970 · Cited by 48
Lee, Y. S., Kim, S., Kim, B., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2017.12.003 · Cited by 48
Giaginis, C., Alexandrou, P. T., Delladetsima, I. K., Giannopoulou, I., Patsouris, E., & Theocharis, S. E. (2013) · Tumor Biology · doi:10.1007/s13277-013-1007-5 · Cited by 46
Garmpis, N., Damaskos, C., Garmpi, A., Dimitroulis, D., Spartalis, E. D., Margonis, G. A., Schizas, D., Deskou, I., Doula, C., Magkouti, E., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11961 · Cited by 42
Self-citationDamaskos, C., Tomos, I. P., Garmpis, N., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12189 · Cited by 41
Self-citationWächter, S., Damanakis, A. I., Elxnat, M., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7040061 · Cited by 40
Kim, S. H., Kang, J. G., Kim, C. S., Ihm, S., Choi, M. G., Yoo, H. J., & Lee, S. J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3101 · Cited by 35
Clinckspoor, I., Verlinden, L., Overbergh, L., Korch, C. T., Bouillon, R., Mathieu, C., Verstuyf, A., & Decallonne, B. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.12.008 · Cited by 35
Kim, S. H., Kang, J. G., Kim, C. S., Ihm, S., Choi, M. G., Yoo, H. J., & Lee, S. J. (2015) · Endocrine · doi:10.1007/s12020-015-0706-7 · Cited by 34
Baldan, F., Mio, C., Allegri, L., et al. (2015) · International Journal of Endocrinology · doi:10.1155/2015/978371 · Cited by 33
Wächter, S., Wunderlich, A. C., Roth, S., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7050115 · Cited by 33
Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
Schizas, D., Mastoraki, A. T., Naar, L., Spartalis, E. D., Tsilimigras, D. I., Karachaliou, G. S., Bagias, G., & Moris, D. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i41.4635 · Cited by 31
Self-citationCatalano, M. G., Pugliese, M., Gallo, M., Brignardello, E., Milla, P., Orlandi, F., Limone, P. P., Arvat, E., Boccuzzi, G., & Piovesan, A. (2016) · International Journal of Endocrinology · doi:10.1155/2016/2930414 · Cited by 31
Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Αgainst Medullary Thyroid Cancer?
Damaskos, C., Valsami, S. I., Spartalis, E. D., Antoniou, E., Tomos, P. I., Karamaroudis, S., Zoumpou, T., Pergialiotis, V., Stergios, K., Michaelides, C., et al. (2016) · Anticancer Research · doi:10.21873/anticanres.11070 · Cited by 29
Self-citationPerona, M., Thomasz, L., Rossich, L. E., Rodriguez, C., Pisarev, M. A., Rosemblit, C., Cremaschi, G., Dagrosa, M. A., & Juvenal, G. J. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.08.007 · Cited by 29
New molecular targeted therapies in thyroid cancer
Milano, A., Chiofalo, M. G., Basile, M., Salzano de Luna, A., Pezzullo, L., & Caponigro, F. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000224449.16329.c5 · Cited by 26
Jang, S., Yu, X.-M., Odorico, S. K., Clark, M., Jaskula‐Sztul, R., Schienebeck, C. M., Kupcho, K. R., Harrison, A. D., Winston‐McPherson, G. N., Tang, W., et al. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.37 · Cited by 24
Kim, S., Park, K. C., Jeon, J. Y., Kim, B., Kim, H. K., Chang, H.-J., Choi, S., Park, C.-S., & Chang, H. (2015) · BMC Cancer · doi:10.1186/s12885-015-1982-6 · Cited by 23
Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells
Dong, X., Korch, C. T., & Meinkoth, J. L. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0320 · Cited by 21
Park, K. C., Kim, S., Jeon, J. Y., Kim, B., Kim, H. K., Chang, H. J., Lee, Y. S., Sk, K., Choi, S. H., Park, C. S., et al. (2017) · Neoplasia · doi:10.1016/j.neo.2016.12.005 · Cited by 21
Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
Zhang, L. M., Boufraqech, M., Lake, R. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7760 · Cited by 20
Effects of HuR downregulation on anaplastic thyroid cancer cells
Allegri, L., Mio, C., Russo, D., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.7289 · Cited by 19
Altucci, L., & Stunnenberg, H. G. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.09.010 · Cited by 18
Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy?
Garmpis, N., Damaskos, C., Garmpi, A., et al. (2018) · PubMed · doi:10.26355/eurrev_201802_14376 · Cited by 16
Self-citationDamante, G. (2010) · Oncology Reports · doi:10.3892/or.2010.1075 · Cited by 15
Kim, S. H., Kang, J. G., Kim, C. S., Ihm, S., Choi, M. G., Yoo, H. J., & Lee, S. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0792-x · Cited by 9
Wang, Y., Jin, T., Dai, X., Yan, D., & Peng, Z. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5711 · Cited by 7
Connolly, C., & Glaholm, J. (2013) · Springer eBooks · doi:10.1007/978-1-4471-2146-6_17 · Cited by 4
Flagged first, then by citations
Research works printed but not linked: 12
- Hundahl SA, Fleming ID, Fremgen AM and Menck HR: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83: 2638- 2648, 1998. PMID: 9874472.
- Kebebew E, Greenspan FS, Clark OH, Woeber KA and McMillan A: Anaplastic thyroid carcinoma: Treatment outcome and prognostic factors. Cancer 103: 1330-1335, 2005. PMID: 15739211, DOI: 10.1002/cncr.20936 · DOI
- Pierie JPEN, Muzikansky A, Gaz RD, Faquin WC and Ott MJ: The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9(1): 57-64, 2002. PMID: 11833496.
- Haigh PI, Ituarte PHG, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY and Clark OH: Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91(12): 2335-2342, 2001. PMID: 11413523
- Tan RK, Finley RK, Driscoll D, Bakamjian V, Hicks WL and Shedd DP: Anaplastic carcinoma of the thyroid: A 24-year experience. Head Neck 17(1): 41-47, 1995. PMID: 7883548.
- Hong L, Schroth GP, Matthews HR, Yau P and Bradbury EM: Studies of the DNA binding properties of histone H4 amino terminus. Thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 "tail" to DNA. J Biol Chem 268(1): 305-314, 1993. PMID: 8416938.
- Damaskos C, Garmpis N, Karatzas T, Nikolidakis L, Kostakis ID, Garmpi A, Karamaroudis S, Boutsikos G, Damaskou Z, Kostakis A and Kouraklis G: Histone deacetylase (HDAC) inhibitors: current evidence for therapeutic activities in pancreatic cancer. Anticancer Res 35(6): 3129-3135, 2015. PMID: 26026072.
- Venugopal B and Evans T: Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 18(11): 1658-1671, 2011. PMID: 21428881.
- Catalano MG, Pugliese M, Poli R, Bosco O, Bertieri R, Fortunati N and Boccuzzi G: Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib. Oncol Rep 21: 515-521, 2009. PMID: 19148530.
- Chan D, Zheng Y, Tyner JW, Chng WJ, Chien WW, Gery S, Leong G, Braunstein GD and Koeffler HP: Belinostat and panobinostat (HDACI): In vitro and in vivo studies in thyroid cancer. J Cancer Res Clin Oncol 139(9): 1507-1514, 2013. PMID: 23824064, DOI: 10.1007/s00432-013-1465-6 · DOI
- Kim HJ and Bae SC: Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 83: 22-32 2011. PMID: 27470546, DOI: 10.1016/ j.biopha.2016.06.014 · DOI
- Garmpi A, Garmpis N, Damaskos C, Valsami S, Spartalis E, Lavaris A, Patelis N, Margonis GA, Apostolou KG, Spartalis M, Andreatos N, Diamantis E, Tsivelekas K, Moschos MM, Nonni A, Tsourouflis G, Markatos K, Antoniou EA, Kontzoglou K, Nikiteas N and Dimitroulis D: Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems. J BUON 23(4): 846-861, 2018. PMID: 30358185.
Cited by
Sorted by citations
Wang, T. K., Xu, S., Fan, Y., Wu, J., Wang, Z., Chen, Y., & Zhang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310476 · Cited by 18
Metadata
- Authors
- SPARTALIS, E., ATHANASIADIS, D. I., CHRYSIKOS, D., SPARTALIS, M., BOUTZIOS, G., SCHIZAS, D., GARMPIS, N., DAMASKOS, C., PASCHOU, S. A., IOANNIDIS, A., TSOUROUFLIS, G., DIMITROULIS, D., & NIKITEAS, N. I.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Aristotle University of Thessaloniki (GR)
- Hospital Agioi Anargyroi (GR)
- ORCID
- Venue
- Anticancer Research
- Published
- 2019-03
- Volume
- 39
- Issue
- 3
- Pages
- 1119-1127
- ISSN
- 0250-7005 (ISSN-L)
- 1791-7530
- OpenAlex
- W2922126564
- Cited by
- 34
- References
- 57
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 1 · 2023: 7 · 2022: 7 · 2021: 5 · 2020: 6 · 2019: 1
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Anticancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- histone deacetylase inhibitors, anaplastic thyroid carcinoma, vorinostat, valproic acid, sodium butyrate, trichostatin A, panobinostat, belinostat, depsipeptides, combination therapy, anticancer activity
- MeSH terms
- Antineoplastic Agents, Humans, Thyroid Neoplasms, Histone Deacetylase Inhibitors, Thyroid Carcinoma, Anaplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
